Hemophilia A - Pipeline Review, H2 2017

Date: November 14, 2017
Pages: 146
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H909533E405EN
Leaflet:

Download PDF Leaflet

Hemophilia A - Pipeline Review, H2 2017
Hemophilia A - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H2 2017, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 5, 7, 5, 19, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Hemophilia A - Overview
Hemophilia A - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hemophilia A - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hemophilia A - Companies Involved in Therapeutics Development
Amarna Therapeutics BV
Apitope International NV
Bayer AG
BioMarin Pharmaceutical Inc
Bioverativ Inc
Catalyst Biosciences Inc
Chugai Pharmaceutical Co Ltd
CSL Ltd
DBV Technologies SA
Dimension Therapeutics Inc
EpiVax Inc
Expression Therapeutics LLC
Green Cross Corp
Idogen AB
Immusoft Corp
LFB SA
mAbxience SA
Novo Nordisk AS
OPKO Biologics Ltd
Pangen Biotech Inc.
Pfizer Inc
Pharming Group NV
Promethera Biosciences SA
Sangamo Therapeutics Inc
Shire Plc
SK Chemicals Co Ltd
Spark Therapeutics Inc
UniQure NV
XL-protein GmbH
Hemophilia A - Drug Profiles
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) biosimilar - Drug Profile
antihemophilic factor (recombinant) biosimilar - Drug Profile
antihemophilic factor (recombinant) biosimilar - Drug Profile
antihemophilic factor (recombinant), PEGylated - Drug Profile
antihemophilic factor (recombinant), pegylated - Drug Profile
antihemophilic factor (recombinant), porcine sequence - Drug Profile
antihemophilic factor (recombinant), single chain - Drug Profile
ATXF-8117 - Drug Profile
BAY-1093884 - Drug Profile
BIVV-001 - Drug Profile
BS-027125 - Drug Profile
Cell Therapy to Target Coagulation Factor VIII for Hemophilia A - Drug Profile
concizumab - Drug Profile
CSL-689 - Drug Profile
damoctocog alfa pegol - Drug Profile
Deimmunized FVIII - Drug Profile
DTX-201 - Drug Profile
emicizumab - Drug Profile
ET-3 - Drug Profile
Gene Therapy for Hematological Disorders - Drug Profile
Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile
Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile
Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile
HepaStem - Drug Profile
IN-3012 - Drug Profile
LR-769 - Drug Profile
marzeptacog alfa - Drug Profile
MG-1113A - Drug Profile
MOD-5014 - Drug Profile
NIBX-2101 - Drug Profile
PBB-8-IN - Drug Profile
PF-06741086 - Drug Profile
Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile
Recombinant Protein to Inhibit Coagulation Factor XIV for Hemophilia A and Hemophilia B - Drug Profile
Recombinant Protein to Replace Coagulation Factor VIII for Hemophilia A - Drug Profile
Recombinant Proteins for Hemophilia A - Drug Profile
SB-525 - Drug Profile
SEL-201 - Drug Profile
SHP-654 - Drug Profile
SPK-8011 - Drug Profile
Stem Cell Therapy to Activate Coagulation Factor VIII for Hemophilia A - Drug Profile
SVF-VIIa - Drug Profile
valoctocogene roxaparvovec - Drug Profile
Hemophilia A - Dormant Projects
Hemophilia A - Discontinued Products
Hemophilia A - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hemophilia A, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Hemophilia A - Pipeline by Amarna Therapeutics BV, H2 2017
Hemophilia A - Pipeline by Apitope International NV, H2 2017
Hemophilia A - Pipeline by Bayer AG, H2 2017
Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H2 2017
Hemophilia A - Pipeline by Bioverativ Inc, H2 2017
Hemophilia A - Pipeline by Catalyst Biosciences Inc, H2 2017
Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
Hemophilia A - Pipeline by CSL Ltd, H2 2017
Hemophilia A - Pipeline by DBV Technologies SA, H2 2017
Hemophilia A - Pipeline by Dimension Therapeutics Inc, H2 2017
Hemophilia A - Pipeline by EpiVax Inc, H2 2017
Hemophilia A - Pipeline by Expression Therapeutics LLC, H2 2017
Hemophilia A - Pipeline by Green Cross Corp, H2 2017
Hemophilia A - Pipeline by Idogen AB, H2 2017
Hemophilia A - Pipeline by Immusoft Corp, H2 2017
Hemophilia A - Pipeline by LFB SA, H2 2017
Hemophilia A - Pipeline by mAbxience SA, H2 2017
Hemophilia A - Pipeline by Novo Nordisk AS, H2 2017
Hemophilia A - Pipeline by OPKO Biologics Ltd, H2 2017
Hemophilia A - Pipeline by Pangen Biotech Inc., H2 2017
Hemophilia A - Pipeline by Pfizer Inc, H2 2017
Hemophilia A - Pipeline by Pharming Group NV, H2 2017
Hemophilia A - Pipeline by Promethera Biosciences SA, H2 2017
Hemophilia A - Pipeline by Sangamo Therapeutics Inc, H2 2017
Hemophilia A - Pipeline by Shire Plc, H2 2017
Hemophilia A - Pipeline by SK Chemicals Co Ltd, H2 2017
Hemophilia A - Pipeline by Spark Therapeutics Inc, H2 2017
Hemophilia A - Pipeline by UniQure NV, H2 2017
Hemophilia A - Pipeline by XL-protein GmbH, H2 2017
Hemophilia A - Dormant Projects, H2 2017
Hemophilia A - Dormant Projects, H2 2017 (Contd..1), H2 2017
Hemophilia A - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Hemophilia A, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Amarna Therapeutics BV
Apitope International NV
Bayer AG
BioMarin Pharmaceutical Inc
Bioverativ Inc
Catalyst Biosciences Inc
Chugai Pharmaceutical Co Ltd
CSL Ltd
DBV Technologies SA
Dimension Therapeutics Inc
EpiVax Inc
Expression Therapeutics LLC
Green Cross Corp
Idogen AB
Immusoft Corp
LFB SA
mAbxience SA
Novo Nordisk AS
OPKO Biologics Ltd
Pangen Biotech Inc.
Pfizer Inc
Pharming Group NV
Promethera Biosciences SA
Sangamo Therapeutics Inc
Shire Plc
SK Chemicals Co Ltd
Spark Therapeutics Inc
UniQure NV
XL-protein GmbH
Skip to top


Hemophilia B - Pipeline Review, H2 2017 US$ 2,000.00 Sep, 2017 · 118 pages

Ask Your Question

Hemophilia A - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: